Apyx Medical Announces Q4 2024 Revenue Between $14.1M-$14.3M, A 3%-4% Decrease YOY; Advanced Energy Revenue Flat At $12.0M-$12.2M; OEM Revenue Down 17% To $2.1M; FY24 Revenue Between $48.0M-$48.2M, An 8% Decrease YOY; Advanced Energy Down 11% To $38.5M-$38.7M; OEM Up 6% To $9.5M.

Author: Benzinga Newsdesk | January 13, 2025 08:39am

Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024.

Preliminary Fourth Quarter 2024 Revenue Summary:

• Total revenue expected to be in a range of approximately $14.1 to $14.3 million, representing a decrease of 4% to 3% year-over-year.
  • Advanced Energy revenue expected to be in a range of approximately $12.0 to $12.2 million, which is relatively flat year-over-year.
  • OEM revenue expected to be approximately $2.1 million, representing a decrease of 17% year-over-year.
    
     

Preliminary Full Year 2024 Revenue Summary:

• Total revenue expected to be in a range of approximately $48.0 to $48.2 million, representing a decrease of 8% year-over-year.
  • Advanced Energy revenue expected to be in a range of approximately $38.5 to $38.7 million, representing a decrease of 11% year-over-year.
  • OEM revenue expected to be approximately $9.5 million, representing growth of 6% year-over-year.

Posted In: APYX